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Abstract
Background: Plausible biological reasons exist regarding why smoking could affect breast cancer risk, but
epidemiological evidence is inconsistent.
Methods: We used serial questionnaire information from the Generations Study cohort (United Kingdom) to estimate
HRs for breast cancer in relation to smoking adjusted for potentially confounding factors, including alcohol intake.
Results: Among 102,927 women recruited 2003–2013, with an average of 7.7 years of follow-up, 1815 developed
invasive breast cancer. The HR (reference group was never smokers) was 1.14 (95% CI 1.03–1.25; P = 0.010) for ever
smokers, 1.24 (95% CI 1.08–1.43; P = 0.002) for starting smoking at ages < 17 years, and 1.23 (1.07–1.41; P = 0.004) for
starting smoking 1–4 years after menarche. Breast cancer risk was not statistically associated with interval from initiation
of smoking to first birth (P-trend = 0.97). Women with a family history of breast cancer (ever smoker vs never smoker
HR 1.35; 95% CI 1.12–1.62; P = 0.002) had a significantly larger HR in relation to ever smokers (P for interaction = 0.039)
than women without (ever smoker vs never smoker HR 1.07; 95% CI 0.96–1.20; P = 0.22). The interaction was prominent
for age at starting smoking (P = 0.003) and starting smoking relative to age at menarche (P = 0.0001).
Conclusions: Smoking was associated with a modest but significantly increased risk of breast cancer, particularly
among women who started smoking at adolescent or peri-menarcheal ages. The relative risk of breast cancer
associated with smoking was greater for women with a family history of the disease.
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Background
The carcinogenic potential of tobacco smoke is unargu-
able [1, 2], and there are plausible biological reasons
why smoking could affect breast cancer risk [2–5].
Authors of reviews of the association between cigarette
smoking and breast cancer up to 2004 did not, however,
generally find conclusive evidence for a causal relation-
ship in humans [5–7]. Authors of more recent epidemio-
logical analyses have reported modest raised risks with
current [8–19] or former [8–15, 20] smoking, but ques-
tions remain about the extent to which this association
is a consequence of confounding by alcohol use, whether
risk is increased if smoking starts in adolescence or
before first childbirth, and whether risk is modified by
family history of breast cancer [1, 2]. We therefore
examined the risk of invasive breast cancer in relation to
smoking in a large cohort study using detailed question-
naire information at recruitment and during follow-up,
with adjustment for alcohol consumption and other po-
tentially confounding factors.
Methods
The Generations Study is a cohort study of over 113,700
women aged 16 years or older from the United
Kingdom, from whom questionnaire information and in-
formed consent were gained at recruitment since 2003
[21]. Initial recruits to the cohort were from women in-
volved in the breast cancer charity that funded the study,
as well as from women who responded to publicity
about the study. Women who joined the study were
asked to nominate female friends and family members,
who were then contacted about joining the study. This
referral method continued with subsequent recruits [21].
The first follow-up questionnaire (2½ years after
recruitment) was completed by 99% of non-deceased
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participants, a second (6 years after recruitment) by
96%, and a third (9½ years after recruitment) by 94% (of
those recruited long enough ago to have entered this
round of follow-up). The study was approved by the
South East Multi-Centre Research Ethics Committee.
Breast and other cancers occurring in the cohort were
identified from recruitment and follow-up question-
naires, spontaneous reports to the study centre, and
from ‘flagging’ (see below) for those lost to questionnaire
follow-up. Confirmation of diagnosis was obtained from
cancer registries in the United Kingdom, ‘flagging’ at the
National Health Service Central Registers (virtually
complete registers of the populations of England and
Wales, and of Scotland, to which study participants can
be linked and on which deaths, cancer registrations and
emigrations are ‘flagged’ and then periodically reported
to authorized medical researchers), pathology reports
and correspondence with patients’ general practitioners.
Information on risk factors for breast cancer was ob-
tained from recruitment and follow-up questionnaires.
In relation to smoking, women were asked if they had
‘ever smoked regularly (i.e., most days for at least
6 months)’, if they still smoked regularly, age started and
stopped, and number of cigarettes smoked per day in
different periods of their lives (during ages 16–24, 25–
49, 50+ years). For analysis, we defined the period of
‘current smoking’ to include both current smokers and
the year immediately after stopping, to avoid potential
‘reverse-causation’ bias from women who may have
stopped smoking during the workup to a formal breast
cancer diagnosis. For alcohol use, we asked women if
they had been a regular drinker ‘in the sense of drinking
at least one glass of alcohol per week on average’, ages
started and stopped, and quantity consumed in different
periods of life (during ages 18–24, 25–49, 50+ years).
We converted the quantity of alcohol consumed in each
period of life into daily grams of alcohol. We split into
three groups the women who reported current drinking
(<60 g/day, ≥ 60 g/day, and amount unknown), and we
classified women who had reported stopping drinking as
former drinkers. For some women, we did not know
their current drinking status during follow-up, but we
knew they had consumed alcohol in the past, and these
women were classified as ‘ever drinkers’. Because we had
collected ages or dates at which certain events or
changes in lifestyle occurred, we were able to update
smoking status, alcohol use, parity, oral contraceptive
(OC) use, menopausal hormone therapy (MHT) use and
menopausal status at the ages these episodes occurred
through the time of the second follow-up questionnaire.
We updated duration of smoking for current smokers,
as well as time since cessation for former smokers, in
yearly increments, using smoking start and stop ages from
the recruitment and second follow-up questionnaires. We
updated cigarettes smoked per day, pack-years smoked, al-
cohol consumption and post-menopausal body mass
index (BMI) at the date of the second follow-up
questionnaire.
Statistical analysis
The present analytic cohort is based on all women who
were recruited into the study during June 2003–Decem-
ber 2013 without prior invasive or in situ breast cancer
or other malignant cancer (except non-melanoma skin
cancer) or prior mastectomy. The recruitment cut-off at
December 2013 was selected because at the time of ana-
lysis the second follow-up was practically complete for
this group of recruits, two-thirds of the cohort had
reached the third follow-up, and we had ‘flagging’ infor-
mation to June 2017. Women entered risk at their date
of recruitment and were censored at the earliest date of
invasive breast cancer or in situ breast cancer; other
malignancy (except non-melanoma skin cancer); death;
most recent follow-up questionnaire (depending on date
of recruitment) if completed, or the date the most recent
follow-up questionnaire was due if cancer and vital
status was known from ‘flagging’; or previously
completed questionnaire if lost to follow-up. We
censored follow-up at in situ breast cancer or other ma-
lignancy because we reasoned that if smoking is related
to risk of in situ breast cancer or other malignancy, and
ensuing treatments or their consequences alter risk of
subsequent invasive breast cancer, including subsequent
follow-up may obscure associations between smoking
and invasive breast cancer.
Left-truncated and right-censored Cox proportional
hazards regression [22] with attained age as the implicit
time scale was used to estimate HR and 95% CI for
smoking and risk of first invasive breast cancer. We ad-
justed for time since recruitment to cohort (0, 1–2, 3+
years); birth cohort (1908–1939, 1940–1949, 1950–1959,
1960–1969, 1970–1996); benign breast disease (yes/no);
family history of breast cancer in first-degree relatives
(yes/no); socio-economic score (Acorn score (https://
acorn.caci.co.uk/) as trend, or missing indicator); age at
menarche (trend, or missing indicator); age at first preg-
nancy (trend, or missing indicator); parity (trend, or
missing indicator); duration of breastfeeding (trend, or
missing indicator); current OC use during follow-up, be-
fore menopause (yes/no); alcohol consumption (trend
for current drinker 1 to < 60 g/day, indicator variables
for never regular, current drinker ≥ 60 g/day, past
drinker, drinker with unknown details); physical activity
[log(metabolic equivalent) trend, missing indicator]; pre-
menopausal BMI at age 20 years (trend, or missing indi-
cator); post-menopausal BMI (trend, or missing indica-
tor); MHT use (never used, ex-user, current oestrogen-
only user, current oestrogen plus progestogen user,
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current user of other types, missing indicator); meno-
pausal status (pre- or post-menopausal); and age at meno-
pause (trend, or missing indicator). BMI was used to
create two separate variables: pre-menopausal BMI (po-
tentially available for all women) and post-menopausal
BMI (only available at post-menopausal ages). We used
BMI at age 20 to represent pre-menopausal BMI. Separ-
ately, if a woman was post-menopausal at entry to the co-
hort we used her BMI at entry for her post-menopausal
BMI (and if she was pre-menopausal at this time, post-
menopausal BMI was unknown). If a woman was post-
menopausal at the time of the follow-up questionnaire, we
updated from this point in time her post-menopausal BMI
with the value from this follow-up questionnaire. Statis-
tical trends were evaluated using continuous values, ex-
cept for duration and time since cessation of smoking,
which were based on discrete time-varying, annually up-
dated values. For trend analyses where there was an unex-
posed group (e.g., never smokers in analyses of smoking
duration), the unexposed group was not assigned a zero
magnitude but was treated as a separate categorical term,
as was any missing value group. In particular we adjusted
our analyses of smoking and breast cancer for alcohol
using daily current alcohol consumption as a continuous
measure if within the range 1 to < 60 g/day, and categor-
ical terms for non-drinkers, for those with consumption ≥
60 g/day (because we did not want a minority of women
who reported very high consumption to influence unduly
the trend with daily consumption), past drinkers, and
those for whom details of consumption were missing, by
fitting appropriate interaction terms in the Cox regression
model. Heterogeneity in HRs by subtype of breast cancer
defined by oestrogen receptor (ER) status or morphology
was assessed using a data augmentation method [23] and
Wald chi-square tests [24]. All statistical tests were two-
sided, and analyses were conducted using Stata/IC version
14.0 software [25].
Results
During 2003–2013, a recruitment questionnaire was
completed by 102,940 women who had no previous in-
vasive or in situ breast cancer or other malignancy (ex-
cept non-melanoma skin cancer). At censoring date,
1.1% of women had died. Of the remainder, cancer and
vital status were known for 96.5% who had completed
the relevant follow-up questionnaire and for a further
2.4% from ‘flagging’ at the National Health Service Cen-
tral Registers. The remaining 1.1% were lost to follow-up
at an earlier date. Thirteen women (including one with
breast cancer) were excluded from subsequent analyses
because of self-contradictory information for parity or
smoking, leaving 102,927 subjects for analysis.
Table 1 presents descriptive characteristics at recruit-
ment of the cohort eligible for analysis. The median age
at recruitment was 47 years (IQR 36–57). A majority of
participants (64.1%) reported never smoking, but only
10.3% were never-regular consumers of alcohol. In rela-
tion to alcohol consumption, 12.5% of never smokers
Table 1 Characteristics of 102,927 women from the Generations
Study, recruited 2003–2013
Study population No. of subjects %
Year of birth
1908–1939 5917 5.8
1940–1949 21,488 20.9
1950–1959 24,735 24.0
1960–1969 23,749 23.1
1970–1996 27,038 26.3
Year of recruitment
2003–2005 33,807 32.9
2006–2007 48,489 47.1
2008–2013 20,631 20.0
Age at recruitment, years
16–34 23,289 22.6
35–44 23,116 22.5
45–54 24,385 23.7
55–64 23,837 23.2
65–74 7308 7.1
75–102 992 1.0
Age at menarche, years
7–11 20,658 20.1
12–14 62,291 60.5
15–19 9353 9.1
Not known or anomalousa 10,625 10.3
Family history of breast cancer in first-degree relatives
No 87,030 84.6
Yes 15,897 15.4
Smoking status, at entry into cohort
Never smoked 66,013 64.1
Current smoker 8491 8.3
Former smoker 28,300 27.5
Ever smoker, status unknown at this time 123 0.1
Alcohol consumption, at entry into cohort
Never regular 10,574 10.3
Current drinker (< 60 g/day) 63,690 61.9
Current drinker (≥ 60 g/day) 1280 1.2
Current drinker, amount unknown 4306 4.2
Former drinker 13,513 13.1
Ever drinker, status unknown at this time 9564 9.3
Total number of subjects 102,927 100.0
Total number of subjects excludes 13 women (including 1 who developed
breast cancer) with self-contradictory information for parity or smoking
aIncludes 2 women reporting menarche before age 5 years, 23 at ages
20–33 years, and 23 reporting never having periods
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were non-drinkers, in contrast to 6.4% of ever smokers.
Among those who reported drinking < 60 g/day, the
median alcohol consumption (g/day) was 14.2 (IQR 8.7–
22.1) among never smokers and 19.0 (IQR 11.9–29.2)
among ever smokers. Additional file 1: Table S1 provides
further descriptive characteristics of the cohort in
relation to age at starting smoking, thelarche, parity,
menopausal status and BMI.
During 788,361 person-years (median 6.6 years; mean
7.7 years) of follow-up, 1815 invasive breast cancers were
diagnosed, of which 1813 were confirmed through
national cancer registration or medical records, and the
remaining 2 were self-reported with treatments that imply
breast cancer. ER status data were available for 99.3%, and
of these 83.7% were ER-positive. Invasive ductal carcin-
oma accounted for 78.8%, and lobular 16.4%, of tumours.
Further descriptive characteristics of the breast cancer
cases are given in Additional file 1: Table S2.
The HR for invasive breast cancer in relation to ever
smoking was 1.17 (95% CI 1.07–1.29; P = 0.0009) when ad-
justed only for attained age, 1.13 (95% CI 1.03–1.24; P =
0.012) when also adjusted for alcohol consumption, and
1.14 (95% CI 1.03–1.25; P = 0.010) when further adjusted
for other potentially confounding variables (see the
Methods section above and Table 2). All subsequent results
are adjusted for attained age, alcohol consumption and the
potentially confounding variables, unless otherwise stated.
Table 2 presents results for breast cancer overall and by
ER status. The HR for ever smoking was raised for ER-
positive (HR 1.12; 95% CI 1.01–1.24; P = 0.035) and ER-
negative (HR 1.25; 95% CI 0.99–1.58; P = 0.063) breast
cancer, and the difference between the HRs was not signifi-
cant (P = 0.40). Breast cancer risk increased significantly
with number of cigarettes smoked per day for all breast
cancer (P-trend = 0.0060) and for ER-positive tumours
(P-trend = 0.023). Breast cancer risks were raised signifi-
cantly after 10+ years’ duration of smoking (10+ years vs
never smoking P = 0.0004). Breast cancer risks did not fur-
ther rise beyond 10 years’ duration, and because of this
non-linear relationship, there was no significant linear trend
with duration of smoking (P-trend = 0.24), nor was there
significant heterogeneity in the trend by ER status. Pack-
years of smoking was associated with breast cancer risk
overall (P-trend = 0.0069) and ER-positive breast cancer
(P-trend = 0.024) but not for ER-negative (P-trend = 0.16)
tumours; there was no significant heterogeneity of the
pack-years trend by ER status (P = 0.66).
The HR within the year after smoking cessation was
2.68 (95% CI 1.60–4.46), based on 15 cases, but for rea-
sons described in the Methods section above, this risk
period was assigned for further analysis to the ‘current
smoker’ group. On this basis, risk of breast cancer was
raised in current (HR 1.12; 95% CI 0.89–1.39; P = 0.34)
and former (HR 1.14; 95% CI 1.03–1.26; P = 0.011)
smokers, although only the latter reached statistical sig-
nificance; there was no significant heterogeneity by ER
status. Breast cancer risks were significantly raised within
the first 20 years after cessation of smoking and decreased
with greater time since cessation, although the trend was
not significant (P-trend = 0.071), and there was no signifi-
cant heterogeneity in this trend by ER status.
There was significant variation in risk of breast cancer
by age at start of smoking (Table 3) (P-heterogeneity =
0.018; not presented in Table 3). Breast cancer risk was
significantly increased if smoking started at age < 17 years
(HR 1.24; 95% CI 1.08–1.43; P = 0.0023) or 17–19 years
(HR 1.15; 95% CI 1.01–1.31; P = 0.030) relative to non-
smokers, but not if it started at older ages. The risk was
significantly increased for ER-positive subjects, only for
smokers starting at ages < 17 years, and no significant
risk increase was noted for ER-negative breast cancer.
When adjusted for pack-years, the breast cancer risk
(HR) for starting smoking at age < 17 years was 1.12
(95% CI 0.96–1.32; P = 0.14), and when adjusted for
duration of smoking, it was 1.16 (95% CI 0.96–1.40;
P = 0.11) (not presented in Table 3).
In our questionnaire, we asked women only about the
amount they smoked per day beginning at age 16 years;
therefore, we could not examine smoking intensity at
younger ages. There was no significant trend in breast
cancer risk, however, in relation to cigarettes smoked
per day at ages 16–24 years. Relative to age at menarche,
breast cancer risks were highest if smoking started at or
before menarche (HR 1.40; 95% CI 0.98–1.99; P = 0.061)
or 1–4 years after (HR 1.23; 95% CI 1.07–1.41; P =
0.0040), with a significant downward trend in breast
cancer risk with increasing interval from age at menar-
che to age at starting smoking (P = 0.031). A similar
pattern was seen for ER-positive, but was less clear for
ER-negative, breast cancer. A weaker relationship was
seen with age at thelarche (e.g., 1–4 years after thelarche;
HR 1.17; 95% CI 1.00–1.37; P = 0.056). When adjusted
for pack-years of smoking, the HRs for age at start of
smoking 1–4 years after menarche (HR 1.12; 95% CI
0.96–1.31; P = 0.15) or thelarche (HR 1.05; 95% CI 0.88–
1.25; P = 0.59) were attenuated (not presented in Table 3).
There was a comparable attenuation after adjusting for
duration of smoking. Among parous women, there was a
significant trend in breast cancer risk with interval from
starting smoking to birth of first child (P-trend = 0.013);
for an interval of 15+ years, the HR was 1.46 (95% CI
1.18–1.81; P = 0.0005). However, these results were not
adjusted for age at first childbirth and parity (not pre-
sented in the tables), and when we adjusted (as shown in
Table 3), there were no significantly raised HRs or trends
for all breast cancer or by ER status.
When we analysed data by morphological type
(Additional file 1: Table S3), we found significant
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Table 3 Relative risk of breast cancer in relation to smoking in relation to age at start of smoking, by oestrogen receptor status
Oestrogen receptor status All breast cancera
Positive Negative
Cases HRb 95% CI P value Cases HRb 95% CI P value Cases HRb 95% CI P value
Age started smoking, yearsc
Never smoked 898 1.00 Baseline 167 1.00 Baseline 1073 1.00 Baseline
< 17 218 1.25 1.08–1.46 0.0032 42 1.22 0.87–1.72 0.25 261 1.24 1.08–1.43 0.0023
17–19 249 1.13 0.98–1.30 0.093 54 1.32 0.97–1.80 0.077 304 1.15 1.01–1.31 0.030
20+ 122 0.95 0.79–1.15 0.62 28 1.25 0.84–1.87 0.28 151 1.00 0.84–1.18 0.96
Age unknown 22 0.94 0.62–1.44 0.79 3 0.73 0.23–2.30 0.59 26 0.94 0.64–1.39 0.76
Trendd P = 0.17 Trendd P = 0.74 Trend among ever smokersd P = 0.18
Trend interaction P = 0.30
Cigarettes per day at ages 16–24 years (among those aged ≥ 25 years at entry)
Never smoked 895 1.00 Baseline 166 1.00 Baseline 1069 1.00 Baseline
1–4 77 1.10 0.87–1.39 0.42 21 1.65 1.05–2.60 0.032 99 1.19 0.97–1.46 0.10
5–9 131 1.23 1.02–1.48 0.027 18 0.92 0.57–1.50 0.75 149 1.16 0.99–1.40 0.069
10–14 170 1.11 0.94–1.31 0.22 31 1.07 0.73–1.57 0.73 203 1.10 0.95–1.29 0.21
15+ 169 1.13 0.96–1.34 0.14 42 1.44 1.02–2.03 0.038 212 1.18 1.01–1.37 0.034
Started at age 25+ 31 0.91 0.64–1.31 0.62 7 1.22 0.57–2.60 0.61 38 0.95 0.69–1.31 0.75
Unknown 31 0.97 0.68–1.39 0.87 7 1.32 0.62–2.79 0.47 38 1.01 0.73–1.40 0.95
Trendd P = 0.70 Trendd P = 0.65 Trendd P = 0.78
Trend interaction P = 0.81
Starting smoking relative to age at menarche, years
Never smoked 898 1.00 Baseline 167 1.00 Baseline 1073 1.00 Baseline
At or before menarche 32 1.60 1.12–2.28 0.010 2 0.50 0.12–2.02 0.33 34 1.40 0.98–1.99 0.061
Years started after menarche
1–4 217 1.21 1.04–1.41 0.015 48 1.38 1.00–1.91 0.049 266 1.23 1.07–1.41 0.0040
5–9 239 1.09 0.94–1.27 0.23 54 1.35 0.99–1.84 0.060 295 1.13 0.99–1.29 0.071
10–14 36 1.03 0.74–1.44 0.86 7 1.13 0.53–2.43 0.75 43 1.04 0.76–1.41 0.82
15+ 12 0.64 0.36–1.13 0.12 6 1.92 0.85–4.34 0.12 18 0.81 0.51–1.30 0.39
Interval unknown 75 1.02 0.79–1.32 0.88 10 0.74 0.38–1.41 0.35 86 0.99 0.77–1.27 0.92
Trendd P = 0.041 Trendd P = 0.80 Trendd P = 0.031
Trend for interaction P = 0.42
Starting smoking relative to age at thelarche, years
Never smoked 898 1.00 Baseline 167 1.00 Baseline 1073 1.00 Baseline
At or before thelarche 16 1.45 0.88–2.39 0.14 1 0.45 0.06–3.24 0.43 17 1.27 0.79–2.06 0.33
Years started after thelarche
1–4 160 1.17 0.99–1.39 0.075 31 1.17 0.79–1.72 0.43 192 1.17 1.00–1.37 0.056
5–9 238 1.06 0.92–1.22 0.47 60 1.42 1.06–1.91 0.020 300 1.11 0.98–1.27 0.10
10–14 37 0.98 0.70–1.36 0.90 11 1.60 0.87–2.95 0.13 48 1.07 0.80–1.43 0.66
15+ 18 0.94 0.59–1.50 0.79 6 1.83 0.81–4.14 0.14 24 1.06 0.71–1.59 0.77
Interval unknown 142 1.22 1.02–1.46 0.031 18 0.87 0.53–1.42 0.59 161 1.17 0.99–1.38 0.074
Trendd P = 0.58 Trendd P = 0.35 Trend among ever smokersd P = 0.82
Trend for interaction P = 0.28
Starting smoking relative to first childbirth, among parous (follow-up time only from first childbirth)
Never smoked 772 1.00 Baseline 148 1.00 Baseline 927 1.00 Baseline
After first childbirth 34 1.20 0.85–1.71 0.30 9 1.85 0.94–3.67 0.076 43 1.28 0.94–1.76 0.12
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associations for ductal breast cancer similar to the re-
sults for breast cancer overall, as well as generally non-
significant results for lobular breast cancer. There were
no significant interactions by morphological type in the
risk of breast cancer with smoking.
There was no raised risk of breast cancer with ever
smoking in non-drinkers (HR 0.97; 95% CI 0.61–1.52; P
= 0.89) but a significantly raised breast cancer risk in
those who had ever been drinkers (HR 1.18; 95% CI
1.07–1.30; P = 0.0010), although the difference in HRs
was not significant (P-interaction = 0.41) (Table 4).
When further stratified by amount of alcohol consumed,
the HRs for ever smoking among current drinkers
remained raised. The results were similar when we ex-
amined breast cancer risk by drinking status for former
smokers relative to never smokers (Additional file 1:
Table S4).
We examined further potential risk factor interactions
with smoking but found no significant interactions with
parity (P = 0.095), although for nulliparous ever smoking
women, there was a statistically significantly increased
risk of breast cancer (P = 0.012) (Additional file 1: Table
S5), or menopausal status (P = 0.73) (Additional file 1:
Table S6). However, although the HR of pre-menopausal
ever smokers was somewhat larger than for post-
menopausal ever smokers, the former did not reach stat-
istical significance (P = 0.088), whereas the latter did (P
= 0.040). Nor did we find significant interactions with
birth cohort (P = 0.092), BMI at age 20 years (P = 0.55)
or post-menopausal ages (P = 0.26), but we did see a sig-
nificant interaction with family history of breast cancer
(P = 0.038). There were significant interactions between
family history and age at start of smoking (P = 0.0029)
and starting smoking relative to age at menarche (P =
0.0001) in relation to risk of breast cancer (Table 5). In
particular, among women with a family history of breast
cancer, HRs were raised if smoking started at age 20+
years (HR 1.56; 95% CI 1.17–2.10; P = 0.0028) or <
20 years (HR 1.26; 95% CI 1.02–1.56: P = 0.029), and if
started 5+ years after menarche (HR 1.53; 95% CI 1.22–
1.91; P = 0.0002), and we noted that these were some-
what different from the results among women without a
family history of breast cancer.
Discussion
In the Generations Study cohort, we found a significant
but modestly raised risk of invasive breast cancer in ever
and former smokers, in women who smoked more than
five cigarettes per day, had 10+ pack-years of use, or had
stopped for < 20 years. Researchers in some previous
studies have reported similar associations with smoking
[8–17, 20], cigarettes per day [9–11, 19], pack-years [9–
13, 17–19, 26–29], and cessation [8, 12, 19, 26, 28], but
not all studies have shown these associations [10, 11, 13,
15–17, 19, 20, 29, 30]. We saw significantly raised risk
with 10+ years’ duration of smoking, but no increasing
trend beyond 10+ years. Increased risks at long dura-
tions (or significant trends) have previously been re-
ported in some studies [8–13, 18–20, 26–28], although
some classified non-smokers as smokers with zero dur-
ation [12, 20, 26, 28], and this may artefactually produce
a significant trend which partly or wholly reflects the
Table 3 Relative risk of breast cancer in relation to smoking in relation to age at start of smoking, by oestrogen receptor status
(Continued)
Oestrogen receptor status All breast cancera
Positive Negative
Cases HRb 95% CI P value Cases HRb 95% CI P value Cases HRb 95% CI P value
Interval from starting smoking to first childbirth, years
1–4 73 1.12 0.88–1.44 0.35 15 1.28 0.74–2.21 0.38 89 1.14 0.91–1.45 0.23
5–9 177 1.06 0.90–1.25 0.51 42 1.35 0.96–1.90 0.089 220 1.10 0.94–1.28 0.22
10–14 130 1.08 0.89–1.30 0.42 22 0.89 0.57–1.40 0.62 152 1.04 0.87–1.24 0.65
15+ 77 1.17 0.91–1.51 0.21 16 1.13 0.66–1.92 0.65 94 1.17 0.93–1.47 0.19
Interval unknown 22 1.07 0.70–1.64 0.75 2 0.54 0.13–2.17 0.38 25 1.02 0.69–1.52 0.92
Trendd P = 0.72 Trendd P = 0.33 Trend among ever smokersd P = 0.97
Trend for interaction P = 0.27
aIncludes 21 breast cancers with unknown or unmeasured oestrogen receptor status
bAdjusted for attained age (Cox regression time scale); time since recruitment to cohort (0, 1–2, 3+ years); birth cohort (1908–1939, 1940–1949,
1950–1959, 1960–1969, 1970–1996); benign breast disease (yes/no); family history of breast cancer in first-degree relatives (yes/no); socio-economic
score (Acorn score as trend, missing); age at menarche (trend, missing); age at first pregnancy (trend, missing); parity (trend, missing); duration of
breastfeeding (trend, missing); current oral contraceptive use before menopause (yes/no); alcohol consumption (never regular, trend current drinker 1
to < 60 g/day, current drinker ≥ 60 g/day, past drinker, drinker with unknown details); physical activity [log(metabolic equivalent) trend, missing];
pre-menopausal body mass index at age 20 years (trend, missing); post-menopausal body mass index (trend, missing); menopausal hormone therapy
use (never used, ex-user, current oestrogen-only user, current oestrogen plus progestogen user, current user of other types, missing); menopausal status
(pre- or post-menopausal) and age at menopause (trend, missing)
cTime updated through follow-up period
dTrend excludes never smoker and unknown group
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difference in risk between non-smokers and smokers
(but this may not be the only reason for an association
with 20+ years [long duration] of smoking).
We found that risk was significantly raised in former
smokers, as previously reported [8–15, 20]. Risk was also
raised with current smoking, but the number of current
smokers in our cohort was small, and this result did not
reach statistical significance, although researchers in
some other studies have reported significantly raised
risks in this group [8–19]. The raised risks for current
and former smokers were similar (HR 1.12 and 1.14, re-
spectively), and the CIs overlapped, suggesting, within
our cohort, no material difference between current and
former smokers in relation to breast cancer risk.
Breast cancer subtypes
We found significant raised risks for ER-positive and
ductal breast cancer, which were the most common
types in our study, but no significant heterogeneity by
ER status or morphological type of the breast cancer in
relation to smoking. The statistical power to examine
differences by ER status or morphology was low in our
cohort because of the relative uncommonness of ER-
negative and non-ductal-type tumours. Some studies
have tended to demonstrate stronger risks for ER-
positive breast cancer [12, 16, 20, 31], but none have
shown significant interactions, and the literature is in-
conclusive [2]. We observed larger HRs for smoking and
pre-menopausal, relative to post-menopausal, breast
cancer, but the former did not reach statistical signifi-
cance, and although the literature is variable, it does in
general suggest a greater relative risk among pre-
menopausal women [1, 2]. However, we found no evi-
dence for a significant interaction with menopausal sta-
tus, similar to other studies [8, 11, 32].
Confounding by alcohol
Alcohol consumption was associated with smoking and
is itself a known risk factor for breast cancer [7]. We ad-
justed for alcohol intake, and although this reduced the
strength of the association between smoking and breast
cancer (from HR 1.17 to 1.14), the association remained
raised and significant. There is, however, concern that
statistical adjustment using self-reported alcohol con-
sumption may not be adequate to control fully for con-
founding by alcohol [7], so to explore further the extent
of potential confounding, we stratified by alcohol con-
sumption (Table 4). Within each stratum of consump-
tion (< 20 g/day, 20–40 g/day, and 40 to < 60 g/day), the
difference in self-reported alcohol intake between never
and ever smokers was ≈ 1 g/day, and we calculated that
this difference in consumption would be associated with
a < 1% change in relative risk of breast cancer (using
the alcohol-breast cancer estimate of relative risk
from a large collaborative re-analysis [7]). Within
each of these strata, it would require ever smokers to
Table 4 Relative risk of breast cancer in relation to ever smoking, by level of alcohol consumption
Strata Total number of cases in strata HR for ever smoking relative to never smoking within
strata of alcohol consumptiona
95% CI P value
Alcoholb
Non-drinker 110 0.97 0.61–1.52 0.89
Ever drinker 1705 1.18 1.07–1.30 0.0010
Interaction Pc = 0.41
Alcoholb
Non-drinker 110 0.97 0.61–1.52 0.89
< 20 g/day 706 1.17 1.00–1.36 0.049
20 to < 40 g/day 356 1.17 0.95–1.44 0.13
40 to < 60 g/day 87 1.12 0.73–1.72 0.61
≥ 60 g/day 27 1.92 0.78–4.76 0.16
Current, amount unknown 180 1.47 1.09–1.98 0.011
Former drinker 295 0.98 0.78–1.25 0.89
Drinker, details missing 54 0.73 0.38–1.42 0.35
Interaction Pc = 0.33
aAdjusted for attained age (Cox regression time scale); time since recruitment to cohort (0, 1–2, 3+ years); birth cohort (1908–1939, 1940–1949, 1950–1959,
1960–1969, 1970–1996); benign breast disease (yes/no); family history of breast cancer in first-degree relatives (yes/no); socio-economic score (Acorn score as
trend, missing); age at menarche (trend, missing); age at first pregnancy (trend, missing); parity (trend, missing); duration of breastfeeding (trend, missing); current
oral contraceptive use before menopause (yes/no); physical activity [log(metabolic equivalent) trend, missing]; pre-menopausal body mass index at age 20 years
(trend, missing); post-menopausal body mass index (trend, missing); menopausal hormone therapy use (never used, ex-user, current oestrogen-only user, current
oestrogen plus progestogen user, current user of other types, missing); menopausal status (pre- or post-menopausal) and age at menopause (trend, missing)
bTime updated through follow-up period
cInteraction across all categories, including missing groups
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Table 5 Relative risk of breast cancer in relation to smoking, by family history of breast cancer
Family history of breast cancera
No Yes
Cases HRb 95% CI P value Cases HRb 95% CI P value
Ever previously smoked cigarettesc
Never 819 1.00 Baseline 239 1.00 Baseline
Ever 554 1.07 0.96–1.20 0.22 203 1.35 1.12–1.62 0.0018
Interaction P = 0.038
Age at start of smoking, yearsc
Never smoker 819 1.00 Baseline 254 1.00 Baseline
< 20 427 1.17 1.04–1.32 0.0098 138 1.26 1.02–1.56 0.029
20+ 96 0.82 0.67–1.02 0.076 55 1.56 1.17–2.10 0.0028
Age unknown 16 0.75 0.46–1.23 0.26 10 1.57 0.84–2.96 0.16
Interaction P = 0.0029
Trendd P = 0.034 Trendd P = 0.38
Trend interaction P = 0.044
Starting smoking relative to age at menarche, years
Never smoker 819 1.00 Baseline 254 1.00 Baseline
Before or < 5 years 239 1.30 1.12–1.51 0.0006 61 1.06 0.80–1.41 0.68
5+ years 244 0.97 0.84–1.13 0.70 112 1.53 1.22–1.91 0.0002
Interval unknown 56 0.83 0.62–1.12 0.22 30 1.51 1.02–2.24 0.041
Interaction P = 0.0001
Trendd P = 0.0021 Trendd P = 0.40
Trend interaction P = 0.0079
Cigarettes per day age among ever smokers, averaged over years when smokinge
Never smoker 819 1.00 Baseline 254 1.00 Baseline
1–4 185 1.01 0.86–1.18 0.95 73 1.32 1.01–1.71 0.040
5+ 210 1.28 1.09–1.49 0.0019 69 1.42 1.09–1.86 0.010
Unknown 144 0.94 0.79–1.13 0.51 61 1.31 0.99–1.74 0.059
Interaction P = 0.13
Trendd P = 0.0019 Trendd P = 0.81
Trend interaction P = 0.18
Duration of smoking among ever smokers, yearsf
Never smoker 819 1.00 Baseline 254 1.00 Baseline
1–9 129 0.94 0.78–1.14 0.54 48 1.20 0.88–1.64 0.24
10+ 385 1.16 1.03–1.32 0.019 140 1.39 1.13–1.71 0.0020
Duration unknown 25 0.76 0.51–1.13 0.17 15 1.51 0.90–2.55 0.12
Interaction P = 0.094
Trendd P = 0.15 Trendd P = 0.86
Trend interaction P = 0.37
Pack-years of smoking among ever smokerse
Never smoker 819 1.00 Baseline 254 1.00 Baseline
1 to < 10 208 1.02 0.87–1.18 0.84 77 1.28 0.99–1.65 0.060
10+ 187 1.30 1.11–1.53 0.0015 65 1.48 1.13–1.95 0.0051
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be drinking 20 g/day more than never smokers to
produce a difference of ≈ 15% (similar to the 12–17%
we saw). This implies that the association we ob-
served between ever smoking and breast cancer may
be too large to be explained by differences in alcohol
intake alone.
We saw no significant association between smoking
and breast cancer risk among non-drinkers, in concord-
ance with a collaborative re-analysis of 43 case-control
and 10 cohort studies [7], the American Cancer Society’s
Cancer Prevention Study II cohort [16], and a subse-
quent pooled analysis of 14 cohort studies [8]. It is pos-
sible that there may be synergistic interaction between
ever smoking and alcohol consumption, and risk of
breast cancer, although only one study has shown the
interaction as statistically significant [8]. There is some
precedent to invoke synergism between smoking and al-
cohol because, for example, there is an established posi-
tive interaction between these two exposures and the
aetiology of head and neck cancers [33]. However, non-
drinking may occur for cultural or religious reasons, or
because of underlying illness or other health issues, and
in the United Kingdom at least, non-drinkers are a mi-
nority group; therefore, this potential interaction could
be a reflection of a particular distribution of breast can-
cer risk factors among non-drinkers (and inadequate
control for confounding among drinkers). Conversely,
three other cohort studies demonstrated significantly
raised risk among non-drinkers [18, 26, 29], although
in two the increased raised risks were only in
subgroups [26, 29].
Smoking in adolescence
On the basis of epidemiological considerations and ani-
mal studies, the period from puberty to first birth may
represent a window of particular susceptibility to breast
cancer [34–37]. At puberty, the breast is made up of
mainly undifferentiated terminal ductal and lobular
structures which animal studies show are sensitive to
chemical carcinogenesis [34]. At these young ages, ioniz-
ing radiation exposure also increases risk of breast can-
cer [37], especially if exposure is within 6 months of
menarche [38]. We found that risk of breast cancer in
ever smokers was greatest if smoking started at age <
17 years or started at peri-menarcheal or, more weakly,
at peri-thelarcheal ages. A number of other studies have
also demonstrated raised risks if smoking started in
adolescence [8–13, 16–18, 20, 26, 28, 29, 32] or around
menarche [11, 16, 26]. However, when we adjusted for
pack-years of smoking, the raised risks for starting
smoking close to age at menarche or thelarche were
somewhat attenuated, suggesting over-adjustment
(because of possible correlation between age starting
smoking and pack-years) or confounding by pack-years.
Previous studies have not made this adjustment, so the
relative importance of early initiation or pack-years of
use remains unclear.
Smoking before first childbirth
Young age at first birth and increasing parity confer
long-term protection against breast cancer [34, 35], and
animal models point to terminal differentiation of breast
tissue at full-term pregnancy being important in this
process [34–36]. Increased risks have been reported for
invasive breast cancer if smoking started before first
childbirth [8–11, 16, 17, 20, 26, 28, 29, 32], but we found
the association was significant only if we did not adjust
for age at first pregnancy. Researchers in a number of pre-
vious studies have adjusted for age at first pregnancy and
still found significant associations with interval to first
Table 5 Relative risk of breast cancer in relation to smoking, by family history of breast cancer (Continued)
Family history of breast cancera
No Yes
Cases HRb 95% CI P value Cases HRb 95% CI P value
Unknown 144 0.93 0.78–1.12 0.46 61 1.30 0.98–1.72 0.069
Interaction P = 0.16
Trendd P = 0.055 Trendd P = 0.54
Trend interaction P = 0.37
aFirst-degree relatives, at recruitment
bAdjusted for attained age (Cox regression time scale); time since recruitment to cohort (0, 1–2, 3+ years); birth cohort (1908–1939, 1940–1949, 1950–1959,
1960–1969, 1970–1996); benign breast disease (yes/no); socio-economic score (Acorn score as trend, missing); age at menarche (trend, missing); age at first
pregnancy (trend, missing); parity (trend, missing); duration of breastfeeding (trend, missing); current oral contraceptive use before menopause (yes/no); alcohol
consumption (never regular, trend current drinker 1 to < 60 g/day, current drinker ≥ 60 g/day, past drinker, drinker with unknown details); physical activity
[log(metabolic equivalent) trend, missing]; pre-menopausal body mass index at age 20 years (trend, missing); post-menopausal body mass index (trend, missing);
menopausal hormone therapy use (never used, ex-user, current oestrogen-only user, current oestrogen plus progestogen user, current user of other types,
missing); menopausal status (pre- or post-menopausal) and age at menopause (trend, missing)
cTime updated through follow-up
dTrend excludes never smoker and unknown groups
eTime updated at the point renewed information was available from follow-up questionnaire
fTime updated in yearly steps
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birth [8, 9, 11–13, 16–18, 20, 26, 28, 29]; however, it is dif-
ficult to determine the adequacy of adjustment. For ex-
ample, in a large pooled analysis of 14 cohort studies,
there was a strong trend with smoking interval before first
birth after adjustment for potential confounders that in-
cluded age at first birth and number of live births (P =
0.0000002), whereas after stratification by age at first birth,
the trends in each stratum were weaker (P = 0.12, 0.02,
and 0.28) [8], which is suggestive of confounding.
Interaction with family history
We found the association between smoking and breast
cancer was significantly larger among women with a
family history of the disease than in those without. In-
vestigators in five previous studies have reported on this
interaction with family history. Two studies showed no
significant interaction but the researchers did not
present stratified results, so we cannot determine if the
direction of interaction supports or contradicts our find-
ings [16, 19]. In three studies, researchers reported sig-
nificant interactions, with one showing increased breast
cancer risk with smoking only among those with a posi-
tive family history [39], whereas two demonstrated that
breast cancer risk was raised only among those with no
family history [15, 18]. Increased risk of breast cancer
with smoking has also been seen in some [40, 41], but
not all (see review [1] and a large meta-analysis [41]),
studies of BRCA1/2 carriers (or by proxy, women with
three or more first-degree relatives with breast or ovar-
ian cancer [42]). There are also reports of significant in-
teractions with smoking and polymorphisms in
carcinogen metabolism genes NAT2 [43] and CYP1A1
[44, 45] as well as breast cancer susceptibility single-
nucleotide polymorphisms [46, 47]. Moreover, BRCA1
and BRCA2 proteins are involved in the repair of DNA
damage, and it is therefore possible that BRCA1/2 carriers
may be more sensitive to effects of carcinogens in
cigarette smoke. Thus, despite the limited and inconsist-
ent literature, it is possible that there are gene-smoking in-
teractions in relation to breast cancer risk (as there is, for
instance, with bladder cancer [48]), and studies may bene-
fit from being focussed on more detailed measures and
timing of exposure (e.g., peri-menarcheal smoking or
pack-years of use) rather than just ever/never smoking.
As in previous studies, we excluded from analysis
women with prevalent breast or other malignant cancer
[11–13, 15–17, 20, 28, 32] or prevalent in situ breast
cancer [13] at recruitment; we restricted the analysis to
invasive breast cancer [7–18, 20, 26, 28, 30]; and we ad-
justed for menopausal status and BMI [8, 10, 11, 13, 16,
18–20, 26, 30, 31], potential confounding variables that
may also be influenced by smoking. There was little
scope for bias from unascertained mortality or exits, or
for erroneous reporting of breast cancer, because follow-
up for vital and breast cancer status was obtained for
99% of participants and confirmation of reported breast
cancers for over 99%. Our smoking information was
gained at recruitment and from follow-up questionnaires
6 years later, and we were able to update smoking status,
so that women who gave up smoking were classified as
former smokers from that point in time. Only a small
number of other cohort studies [13, 16, 20] have been
able to update smoking exposure through follow-up.
One limitation of our study is that we have no direct in-
formation on passive (secondhand) smoking, and there-
fore our risk estimates might be underestimated if never
smokers were exposed to passive smoking and if this ex-
posure affects risk of breast cancer [49].
If our results are not due to chance, residual con-
founding, or unidentified bias, they suggest that certain
biological mechanisms deserve further attention, such as
those involving exposure at peri-menarcheal ages, and
gene-environment interactions, either of which may be
the direct result of chemical carcinogenesis or an indir-
ect consequence on hormonal pathways during this sus-
ceptible period of breast development.
Conclusions
We found that smoking was associated with a modest
but significantly increased risk of breast cancer, particu-
larly among those who started at adolescent or peri-
menarcheal ages, and that the relative risk of breast can-
cer associated with smoking was significantly greater for
women with a family history of the disease.
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